Praćenje promjena koncentracije topljivoga receptora za TGF beta III specifičnoga biomarkera u plazmi bolesnica s karcinomom dojke [Monitoring of plasma concentration changes of specific biomarker TGF beta III soluble receptor in breast cancer patients]

Jurišić, Darko (2016) Praćenje promjena koncentracije topljivoga receptora za TGF beta III specifičnoga biomarkera u plazmi bolesnica s karcinomom dojke [Monitoring of plasma concentration changes of specific biomarker TGF beta III soluble receptor in breast cancer patients]. PhD thesis, Sveučilište u Zagrebu.

[img] PDF
Download (1MB)

Abstract

Background and aim Breast cancer is the most common female cancer disease of which are affected one quarter of women treated for cancer in the world and Croatia. The aim of this study was to explore the relationship of the molecule TGF β rIII in samples of plasma of the patients with breast cancer and tumour tissue with prognosis of the disease. Subjects and Methods The study included 62 female patients with breast cancer and 36 respondents in the control group. ELISA method was used to determine the concentration of the TGF β rIII in the patients' plasma before and after the surgery, while immunohistochemical analysis was used for expression of TGF β rIII protein in breast tumor samples. Results In this research for the first time we measured the values of the TGF β rIII in plasma of the patients with breast cancer and in plasma of healthy respondents. The average concentration of the TGF β rIII in plasma of the patients with breast cancer was 7,63 ng/ml (range 14,41 ng/ml), which was significantly lower concentration compared to the control group (p<0,001). Patients with breast cancer with preoperative concentration of the TGF β rIII in plasma lower than 7,83 ng/ml had statistically significantly lower survival rate without adversely primary outcome (metastasis, local recurrence or appearance of new primary tumors) compared to other patients (p=0,045). Patients with poor prognostic parameters (LN+, ER/PR-, Her2+) and with preoperative concentration of the TGF β rIII in plasma higher than 7,83 ng/ml had statistically significantly better survival rate without adversely primary outcome compared to patients with lower concentration of the TGF β rIII in plasma (p=0,016). Conclusion This study demonstrated that TGF β rIII in the plasma of patients with breast cancer disease could be a new predictor of outcome in a group of patients with low-risk disease and is an interesting subject for future research.

Abstract in Croatian

Uvod i cilj istraživanja Karcinom dojke najčešće je maligno oboljenje žena od kojeg obolijeva četvrtina novooboljelih ženskih osoba u svijetu i Hrvatskoj. Cilj ove studije bio je istražiti povezanost molekule TGF β rIII u uzorcima plazme bolesnica s karcinomom dojke i tkiva tumora s prognozom bolesti. Ispitanici i metode U istraživanju su bile uključene 62 bolesnice sa zloćudnim tumorom dojke i 36 zdravih ispitanica u kontrolnoj skupini. ELISA metodom određivali smo koncentraciju TGF β rIII u plazmi bolesnica prije i nakon operativnog zahvata, a imunohistokemijski izražajnost TGFβ rIII proteina u uzorcima tumora dojke. Rezultati U ovom istraživanju po prvi puta smo izmjerili vrijednosti TGF β rIII u plazmi bolesnica s karcinomom dojke te u plazmi zdravih ispitanica. Prosječna koncentracija TGF β rIII u plazmi bolesnica s karcinomom dojke iznosila je 7,63 ng/ml (raspon 14,41 ng/ml), što je bilo značajno niže u odnosu na kontrolnu skupinu (p<0,001). Bolesnice s preoperativno izmjerenom koncentracijom TGF β rIII u plazmi nižom od 7,83 ng/ml imale su statistički značajno manji udio preživjelih bez nepovoljnog primarnog ishoda (metastaza, lokalni recidiv ili pojava novog primarnog tumora) u usporedbi s ostalim bolesnicama (p=0,045). Bolesnice koje su imale loše prognostičke parametre (LN+, ER/PR-, Her2+), a čija je koncentracija TGF β rIII u plazmi prije operativnog zahvata bila veća od 7,83 ng/ml, imale su značajno bolje preživljenje bez nepovoljnog primarnog ishoda u odnosu na bolesnice s tumorima istih karakteristika ali nižom koncentracijom TGF β rIII u plazmi (p=0,016). Zaključak U ovom istraživanju pokazali smo da bi se TGF β rIII u plazmi bolesnica s karcinomom dojke mogao koristiti kao novi prediktor ishoda u skupini bolesnica s niskim rizikom bolesti te je zanimljiv predmet budućih istraživanja.

Item Type: Thesis (PhD)
Mentors:
Mentor
Grgurević, Lovorka
Departments: Izvan medicinskog fakulteta
Depositing User: dr.med. Helena Markulin
University: Sveučilište u Zagrebu
Institution: Medicinski fakultet
Number of Pages: 130
Status: Unpublished
Creators:
CreatorsEmail
Jurišić, DarkoUNSPECIFIED
Date: 10 May 2016
Date Deposited: 27 Jun 2018 11:45
Last Modified: 27 Jun 2018 11:45
Subjects: /
Related URLs:
    URI: http://medlib.mef.hr/id/eprint/2981

    Actions (login required)

    View Item View Item

    Downloads

    Downloads per month over past year